Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
- PMID: 27876626
- PMCID: PMC5846100
- DOI: 10.1016/j.jaci.2016.10.022
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
Abstract
NLRC4-inflammasome hyperactivity causes infantile-onset Macrophage Activation Syndrome and enterocolitis with extraordinary serum IL-18 elevation (NLRC4-MAS). Herein, we report a critically ill infant with severe, refractory NLRC4-MAS who showed sustained response to treatment with experimental IL-18 inhibition.
Figures
Comment in
-
IL-18 binding protein reverses the life-threatening hyperinflammation of a baby with the NLRC4 mutation.J Allergy Clin Immunol. 2017 Jul;140(1):316. doi: 10.1016/j.jaci.2017.02.037. Epub 2017 Apr 28. J Allergy Clin Immunol. 2017. PMID: 28457594 No abstract available.
-
Reply.J Allergy Clin Immunol. 2017 Jul;140(1):316-317. doi: 10.1016/j.jaci.2017.03.016. Epub 2017 Apr 29. J Allergy Clin Immunol. 2017. PMID: 28460789 No abstract available.
References
-
- Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004 Aug 1;104(3):735–743. PubMed PMID: 15069016. Epub 2004/04/08. eng. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
